ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
2019 · Annals of Oncology · 1,101 citations
https://doi.org/10.1093/annonc/mdz062
S
Sandro Pignata
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
896
Papers
35.1K
Citations
81
h-index
358
i10-index
Sandro Pignata is an academic researcher from Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale". The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & PARP inhibition in cancer therapy & Endometrial and Cervical Cancer Treatments. The author has an h-index of 81, co-authored 762 publications.
ORCID: 0000-0002-8836-2633Papers by this author
worksESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
2019 · Annals of Oncology · 1,101 citations
https://doi.org/10.1093/annonc/mdz062
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · New England Journal of Medicine · 336 citations
https://doi.org/10.1056/nejmoa2309169
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 · Journal of Clinical Oncology · 334 citations
https://doi.org/10.1200/jco.22.01900
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
2023 · Annals of Oncology · 299 citations
https://doi.org/10.1016/j.annonc.2023.05.005
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary
2013 · British Journal of Cancer · 163 citations
https://doi.org/10.1038/bjc.2013.241
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat